Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo targets rare, aggressive lung cancer

NCT ID NCT06049966

Disease control Sponsor: Oncology Center of Biochemical Education And Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial investigates whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (carboplatin and etoposide) helps people with a rare and aggressive lung cancer called large cell neuroendocrine carcinoma (LCNEC). The study enrolls adults with advanced or metastatic LCNEC who have not had prior treatment. Researchers measure how long patients live without the cancer worsening, overall survival, and tumor shrinkage. They also look at blood markers called miR-21 and miR-375 to see if they can predict treatment response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atezolizumab (Tecentriq) plus carboplatin and etoposide
What this could lead to
If successful, this could offer a new treatment option for a rare and aggressive lung cancer, potentially improving survival and response rates.
What could go wrong
This is an early-phase, small study (22 people) with no randomization. The drug may not work better than chemo alone, and side effects from immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

22 people

The number who actually took part.

Started

Nov 2019

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohorts A and B: Inclusion Criteria: * Histologically confirmed Stage IV (metastatic) or unresectable locally advanced LCNEC * No prior treatment * With or without brain metastasis, if symptomatic patients should be treated with WBRT first * Performance Status ≤ 2 * Life expectancy \> 3 months * Written informed consent * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Exclusion Criteria: * Prior treatment with chemotherapy, immunotherapy, targeted small molecule therapy, or radiation therapy (except WBRT for brain metastasis from LCNEC) * Active or history of autoimmune disease or immune deficiency * Treatment with systemic immunosuppressive medications with the following exceptions: Patients who have received acute, low-dose systemic immunosuppressant medication (≤ 10 mg/day oral prednisone or equivalent) or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Medical Monitor approval has been obtained. * Major surgical procedure other than for diagnosis within 4 weeks before initiation of study treatment, or anticipation of need for a major surgical procedure during the study * Active malignancy or malignancy within 3 years * Active tuberculosis * Current severe, uncontrolled systemic disease other than cancer * Known clinically significant liver disease * Treatment with any other investigational agent or participation in another clinical study with therapeutic intent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Large cell neuroendocrine carcinoma of the lung are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary large cell neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Large cell neuroendocrine carcinoma of the lung

Contacts and locations

Locations

  • National and Kapodistrian University of Athens

    Athens, 11527, Greece

  • OCEBER

    Athens, Athens, 11527, Greece

  • Sotiria Thoracic Diseases General Hospital of Athens

    Athens, 115 27, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.